AB063. P-34. A multicenter, phase 1b/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment naïve advanced or metastatic biliary tract cancer (BTC)

BACKGROUND: Biliary tract cancer (BTC) is a rapidly progressing cancer with limited response to chemotherapy. First line therapy (gem/cis) was defined in the ABC-02 study (Valle et al.), where a 26% response was seen. HER family receptors are overexpressed and may be involved in tumour proliferation...

詳細記述

保存先:
書誌詳細
出版年:Hepatobiliary Surg Nutr
主要な著者: Oh, Do-Youn, Yong, Wei-Peng, Chen, Li-Tzong, Kim, Ji-Won, Chang, Alex Yuang-Chi, Park, Jin Hyun, Hsieh, Chih-Yi, Shih, Hsuan-Jen, McIntyre, Nicola, Chen, Ying-Chen, Chang, Wei-Ling, McHale, Mark, Lindmark, Bertil
フォーマット: Artigo
言語:Inglês
出版事項: AME Publishing Company 2019
主題:
Poster Abstracts
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6421180/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/hbsn.2019.AB063
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料